Free shipping on all orders over $ 500

MK-0429

Cat. No. M10957
MK-0429 Structure
Synonym:

L-000845704

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

MK-0429 (L-000845704) is an oral, highly effective, selective, non-peptide integrin ubiquitous antagonist for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1 IC5 0 The values are 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM, and 12.2 nM, respectively.

Chemical Information
Molecular Weight 439.52
Formula C23H29N5O4
CAS Number 227963-15-7
Solubility (25°C) DMSO ≥ 60 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Anya Gupta, et al. J Org Chem. Thermodynamic Understanding of an Aza-Michael Reaction Enables Five-Step Synthesis of the Potent Integrin Inhibitor MK-0429

[2] Ji Zhang, et al. Sci Rep. Discovery of a new class of integrin antibodies for fibrosis

[3] Izabela Łasiska, et al. Anticancer Agents Med Chem. Integrins as A New Target for Cancer Treatment

[4] Xiaoyan Zhou, et al. Pharmacol Res Perspect. An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model

[5] Maureen Pickarski, et al. Oncol Rep. Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis

Related Integrin Products
Anti-Mouse IL-1a Antibody

Anti-Mouse IL-1a Antibody is an anti-mouse IL-1a IgG1 antibody inhibitor derived from host Armenian Hamster.

Etaracizumab

Etaracizumab (LM 609) is an αvβ3 integrin IgG1 monoclonal antibody. Etaracizumab inhibits angiogenesis and melanoma tumor growth. Etaracizumab can be used to research anticancer.

Veltuzumab

Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL).

Tadocizumab

Tadocizumab (C4G1; YM-337) is a humanized monoclonal antibody tageting integrin αIIbβ3. Tadocizumab has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research.

Rovelizumab

Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke.

  Catalog
Abmole Inhibitor Catalog




Keywords: MK-0429, L-000845704 supplier, Integrin, inhibitors, activators

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.